Author of

• 16751

  +

  P1.05 - Poster Session with Presenters Present (ID 457)

  • Event: WCLC 2016
  • Type: Poster Presenters Present
  • Track: Early Stage NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 12/05/2016, 14:30 - 15:45, Hall B (Poster Area)

  • 16761

    +

    P1.05-010 - Aberrant Promoter Methylation of ESR1 and CDH13 Gene Are an Independent Prognostic Marker in Surgically Resected Non-Small Cell Lung Cancer (ID 3840)

    14:30 - 14:30  |  Author(s): S. Ognjanovic
    • Abstract
    • Slides

    Background:
    Aberrant promoter hypermethylation of tumor suppressor genes are promising markers for lung cancer diagnosis and prognosis. The purpose of this study was to determine the correlation between the aberrant promoter methylation of multiple genes and 5-year survival rate in patients with nonsmall cell lung carcinoma (NSCLC) after a surgical resection.
    
    Methods:
    Primary tumor samples (n=65) and corresponding nonmalignant lung tissues (n=65) were obtained from NSCLC patients who underwent curative surgery. The methylation status of seven genes (SOX1, RASSF1A, HOXA9, CDH13, MGMT, ESR1 i DAPK) was quantified using bisulfite pyrosequencing. Cox proportional hazards models were used to analyze the associations between gene methylation status and overall patient survival.
    
    Results:
    In the Cox proportional hazards model, ESR1 methylation in tumor tissue was associated with significantly poorer survival, with hazard ratio of 1.09 (95% confidence interval 1.02-1.16, p=0.01). This effect was independent of TNM stage, which was also a predictor of survival. We also found that aberrant methylation in CDH13 gene in tumor tissue was associated with inferior survival in surgically resected NSCLC pateints. In contrast, there were no significant survival differences noted between the methylation-positive and methylation-negative tumors for the other genes tested.
    
    Conclusion:
    Our study shows that aberrant promoter methylation of ESR1 and CDH13 genes may be associated with inferior survival, showing promise as a useful prognostic biomarker in patients with NSCLC.
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.